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Abstract
Background: We attempted to clone candidate genes on 10p14–15 which may regulate hTERT
expression, through exon trapping using 3 BAC clones covering the region. After obtaining 20
exons, we examined the function of RGM249 (RGM: RNA gene for miRNAs) we cloned from
primary cultured human hepatocytes and hepatoma cell lines. We confirmed approximately 20 bp
products digested by Dicer, and investigated the function of this cloned gene and its involvement in
hTERT expression by transfecting the hepatoma cell lines with full-length dsRNA, gene-specific
designed siRNA, and shRNA-generating plasmid.
Results: RGM249 showed cancer-dominant intense expression similar to hTERT in cancer cell
lines, whereas very weak expression was evident in human primary hepatocytes without
telomerase activity. This gene was predicted to be a noncoding precursor RNA gene. Interestingly,
RGM249 dsRNA, siRNA, and shRNA inhibited more than 80% of hTERT mRNA expression. In
contrast, primary cultured cells overexpressing the gene showed no significant change in hTERT
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Open AccessmRNA expression; the overexpression of the gene strongly suppressed hTERT mRNA in poorly
differentiated cells.
Conclusion: These findings indicate that RGM249 might be a microRNA precursor gene involved
in the differentiation and function upstream of hTERT.
Background
Telomerase, which adds repeated telomere sequences to
chromosome ends, is a ribonucleoprotein enzyme that
includes an endogeneous RNA (hTR) which acts as a
template and a reverse transcriptase (hTERT), and are
crucial molecules [1-4]. Telomerase activity has been
detected in immortalized and tumor cells and its strong
expression represents an important difference between
normal and cancer cells [5]. Although it is thought that
telomere maintenance is predominantly due to telomer-
ase activity [6, 7], which is mainly regulated by hTERT
expression in the presence of hTR [8, 9], some gaps exist
in the steps between immortalization, carcinogenesis,
and cellular senescence [10]. Therefore, these unknown
steps must first be fully identified before translational
applications are possible [11-13]. As several reports have
indicated that human chromosome 10p carries a set of
genes involved in regulating telomerase activity [14-16],
we performed microcell-mediated chromosome transfer,
radiated microcell fusion, and bacterial artificial chro-
mosome (BAC) transfer assuming loss of heterozygosity
(LOH), and examined telomerase expression in transfec-
tants to determine whether hTR- and hTERT-regulating
genes are located on 10p15 [17]. After we determined
the telomerase regulatory regions on chromosome
10p15.1 using DNA markers, we confirmed that the
chromosomal fragments containing the regions induce
senescence in the transfectants [18, 19]. We then identified
that radiated chromosomal fragments containing
D10S1728 (a genomic region on chromosome 10p15)
induced senescence in transfectants, and performed the
sequencing of 3 BAC clones containing D10S1728 [20-22]
(data not shown), exon trapping using the BAC clones
[23-25], Northern blotting, and RT-PCR before cloning
several full-length genes. One of the genes we cloned was
named RGM249 (RNA gene for miRNAs which was 249 bp
in length), and showed stronger gene expression in
cancerous lesions than in normal liver.
We used the RNA interference (RNAi) method, which is a
sequence-specific post-transcriptional gene silencing
mechanism triggered by double-stranded RNA
(dsRNA), to cause degradation of mRNAs homologous
i ns e q u e n c et od s R N Aa n dt oe f f e c t i v e l yi n h i b i tg e n e -
specific expression [26]. Because dsRNA transfection is a
common strategy for suppressing genes of interest, the
small interfering RNA (siRNA) technique is an excellent
gene-specific method for determining the function of the
targeted gene by inhibiting its expression [27-30]. After
focusing on RGM249 (RGM: RNA gene for miRNAs; 249
for 249 bp) among the genes cloned on 10p14–15 for
further analyses, we examined the telomerase regulatory
function of RGM249 using the overexpressing cassette
and the gene-specific siRNA.
In this report, we present a summary of our cloning
research and introduce functional analyses regarding the
identified gene regulating hTERT mRNA.
Results and discussion
Screening of BAC library and transfection into HMc-Li7
We investigated the 3 BAC clones using a sequence-
tagged-site marker (D10S1728) by PCR, based on
previous reports [18, 19]. From these studies, we
determined that the 3 BAC clones (M-6, H-11, and
J-21) contained D10S1728.
Whole sequencing of H-11 and exon trapping
Approximately 90%~95% of the BAC clone H-11
sequence and supercontig were determined (studies
were performed by the University of Colorado Cancer
Center Sequencing Core). D10S1728 was regarded as the
sequence on 10p15.3. We reconfirmed that the sequence
and supercontig were derived from the original BAC
clones by Southern blotting and PCR, and 20 exons were
thereafteridentified(fig1-(a)).Weperformedacomputer
analysis for each contig, and the endosequences of the 3
BAC clones and the exon sequences we trapped showed
that they closely overlapped each other (fig 1-(b)).
Northern blot analysis and one-step real-time RT-PCR
U s i n gap r o b ea g a i n s te a c he x o ns e q u e n c e( 4 7 –376 bp),
Northern blotting was performed, which demonstrated
that several exons showed a very faint signal (data not
shown). In particular, a very faint single hybridization
signal in human Multiple Tissue Northern (MTN) blot
(Clontech) migrating at about 250 bp was determined
for RGM249. One-step real-time RT-PCR showed a very
low expression rate, that is, less than 20,000 copies per
50 ng of total RNA extracted from human organs (fig 2-
(b)). In normal liver, approximately 60 copies per 50 ng
of total RNA of transcripts were expressed. In contrast,
the study on human primary hepatocyte cultures,
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hepatoma cell lines (HepG2, Huh7, HMc-Li7 and
Alexander), indicated that hepatoma cells expressed
RGM249 at much higher levels than normal human
hepatocytes (fig 2-(c)). In 39 hepatomas, the expression
rate was higher (mean ± SEM: 609.2 ± 261.5 copy
number per 100 ng/μl) than in the 35 adjacent
noncancerous lesions (138.9 ± 46.5) (P = 0.007 by t-
test and P = 0.040 by paired t-test) (fig 2-(d)).
5' & 3' RACE and cDNA library screening
5' and 3' RACE was performed using liver c DNA libraries
(Clontech). Screening of the cDNA libraries yielded a
clone with a full sequence length of 249 bp. A
comparison of the cDNA sequence with the genomic
sequence from H-11 revealed that the gene of interest
w a se x t e n d e da c r o s s9k b .T h ec D N An a m e dR G M 2 4 9
consisted of 2 exons and the RNA was not poly-
adenylated (fig 1-(b)). The sequence with about 40%
of the GC ratio is shown in fig 3-(a), indicating that this
gene might be a noncoding RNA (ncRNA) gene, as
shown in fig 3-(b). PCR-Single Strand Conformation
Polymorphism (PCR-SSCP) and sequencing showed that
the gene had no mutations other than a one-base
addition at the last site of exon 1 in 10 normal liver
tissue samples (10%; 1/10) and no mutations in 4 tumor
cell lines (0%; 0/4). Although the cDNA showed no
homology with either additional human loci except for
Figure 1
Schematic diagram showing the chromosomal location (10p15.3) of exons including RGM249. (a) Mapping of
exons trapped between 10p15.1 and 10p15.3. Reference was used as an assembly database. This region does not contain any
known genes except GATA3. Solid arrows indicate both ends of the sequences which BAC clones cover and show that
9447200 links to 9447201 in NT077569.2. (b) Schematic diagram showing the chromosomal location (10p15.3) of RGM249,
which consists of 2 exons, genomic fragments (AL355591.3 and AL138774.5), and a genomic marker (D10S1728) containing
the gene and BAC clones (H-11, M-6, and J-21) used for the mapping. The full length of the gene is 249 bp. Solid and dashed
lines represent the exons trapped and their neighboring gene (GATA3), respectively.
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predicted to be digested from RGM249 by Dicer matched at
least 3 miRNAs in the miRNA database (miRBase; mature
miRNAsorstem-loopsequences)http://microrna.sanger.ac.
uk/sequences/search.shtml. Although their functions
remain unknown because we have not fully clarified
whether RGM249 is actually processed by Dicer in vivo,
given that it can be processed by Dicer in vitro. On the other
hand, a motif search predicted no motifs in the RGM249
gene. Because this gene generated no protein, the secondary
structure of RGM249 was drawn based on the structure
provided at http://www.tbi.univie.ac.at/~ivo/RNA/ (fig 3-
(b)).Moreover,becausethefull-lengthRNAwasdigestedby
Dicer enzymes, 20–23 bp sharp bands could be observed,
indicating that nucleotides generated from RGM249 RNA
may be miRNAs (fig 3-(c)).
GeneBank accession number
Sequence data have been deposited with the EMBL/
GenBank Data Libraries under accession no. EF433558.
Figure 2
A quantitative estimation in normal cells, cancer cells, and tissues. To quantify RGM249 mRNA expression in
hepatocytes, hepatoma cells, and liver tissues, the copy number in 10 ng of total RNA was evaluated. (a) One-step real-time
PCR was performed based on the linear correlation (P > 0.990) of the RNA controls. (b) RGM249 mRNA expression was
examined in human representative organs using one-step real-time RT-PCR. The vertical line shows the copy number per
50 ng/μl total RNA (c) RGM249 mRNA expression in liver-related cells (from the left: adult liver tissues, fetal liver tissues,
primary cultured hepatocytes [T], cytoplasm segment of primary hepatocytes [C], nuclear segment of primary hepatocytes
[N], HLF cells, HMc-Li7 cells, HepG2 cells, and Alexander cells). (d) RGM249 mRNA expression in surgically resected liver
tissues containing 33 pairs of hepatomas and adjacent noncancerous tissue. C: cancerous lesion, NC: adjacent noncancerous
lesion. Cancerous lesions showed a significant upregulati o no fR G M 2 4 9m R N A ,c o m p a r e dw i t hn o n c a n c e r o u sl e s i o n s ,a s
determined by the t-test (P = 0.007) and paired t-test (P = 0.040). Box represents 95% confidence intervals.
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In many hTERT- or hTR-regulating molecules reported
previously, only two factors, hTERT and ribosomal
protein L22 (RPL22), were transcriptionally suppressed
in the hepatoma-derived cell lines (HLF) transfected
with full-length RGM249 dsRNA (fig 4-(a))[31]. To
reconfirm the findings in dsRNA method, the siRNA
method was performed. Results showed that their
expressions were suppressed in HLF cells transfected
with Stealth siRNA ① (fig 4-(b),(c)).
RGM249 siRNA suppressed more than 90% of hTERT
mRNA, approximately 50% of RPL22 mRNA, and RGM249
transcripts (fig 4-(c)) unlike hTR expression. However,
RPL22 expression in cells transfected with Stealth siRNA ①
was weaker(50%) thaninthose transfected with full-length
dsRNA (fig 4-(c)). siRNA ① + ② had less efficient
knockdown due to the interaction between both siRNAs.
Thesefindings areconsistent withour results obtainedfrom
dsRNA induction, an experiment performed under condi-
tions of almost negligible cytokine storm. A similar result
was obtained about 48 hours after transfection.
Subsequently, we examined the inhibitory effect of
shRNA transfection. Compared with LacZ shRNA, we
found that RGM249 shRNA and mt-1RGM249 shRNA
Figure 3
Outlines of cloned RGM249, a possible miRNA precursor or telomerase regulated gene. (a) RGM249 sequence is
shown, and the sequences used for the siRNA and shRNA designs are underlined. (b) Predictive secondary structure of
RGM249 was drawn by Vienna RNA Secondary prediction and comparison http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi. Bold
line corresponds to the sequence used as the most functional siRNA or shRNA. The underlined parts show the sense and
antisense sequences generating shRNA. Star (⋆) shows deletion of T or C in mt-1RGM249 or mt-2RGM249, respectively.
(c) From the digestion by RNase III (Dicer), RGM249 mRNA generates 3 products ranging from 17 to 23 bp, suggesting that
this gene may function as a noncoding precursor RNA gene which produces miRNAs.
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Figure 4
Expression of telomerase-related genes in RNAi methods. (a) Inhibitory effect of full-length RGM249 dsRNA (100 nM
dsRNA) on the transcriptional expression of telomerase-related genes in a hepatocellular carcinoma cell line (HMc-Li7) as
determined by RT-PCR. RGM249, hTERT, and RPL22 were significantly suppressed. The lower blotting demonstrates gene
expression using a transfection reagent without dsRNA. (b) RT-PCR showing the inhibitory effects of RGM249-specific siRNA on
RGM249 mRNA, hTERT mRNA, and RPL22 mRNA in HLF cells, which express RGM249 mRNA in 4 hepatoma cell lines in the
strongest manner. siRNA ① and siRNA ② correspond to those in Table 2. (c) Quantitative evaluation of the suppressive effect of
siRNA in which the measurement, in the case without siRNA, was regarded as 100% for standardization (N = 5), suggesting that
siRNA ① has a functional sequence. RGM249 siRNA transcriptionally suppressed more than 80% of hTERT expression and
approximately 50% of RPL22 expression. RGM249 mRNA, ▯ hTERT mRNA, RPL22 mRNA. d) Quantitative evaluation of the
inhibitory effect of RGM249 shRNA on RGM249 mRNA, hTERT mRNA, and RPL22 mRNA. From left, transfection using only
transfection reagents, LacZ shRNA as the gene control, wtRGM249 shRNA, and mt-1RGM249 or mt-2RGM249 shRNA with a
different mutation (a nucleotide T or C) in the functional sequence. A total of 5 transfections were performed and data were
statistically analyzed using the Mann-Whitney test. Compared with LacZ shRNA, RGM249 and mt-1RGM249 shRNA significantly
suppressed hTERT mRNA (P = 0.002 and P = 0.034, respectively). mt-1RGM249 and mt-2RGM249 correspond to those in Table 2.
▯ RGM249 mRNA, hTERT mRNA, RPL22 mRNA, *: P < 0.05; **: P < 0.01. Quantitative evaluation of the suppressive effect of
shRNA in which the measurement, in the case without siRNA, was regarded as 100% for standardization (N = 5). (e) Telomerase
activity was quantitatively compared using image analyzer between transfectants with LacZ shRNA (in proliferative state) and
RGM249 shRNA (in senesced state) and RGM249 shRNA, and was compared with the parental cells (112 and 54, respectively,
which had an intensity of 100). Although the results depended on the timing of cell harvests after transfection, telomerase activity in
transfectants with RGM249 shRNA was reduced to approximately half compared with that in parental cells, and we observed a
periodicity of 6 bp due to reduced telomerase in the shRNA lane. NC: telomerase negative control.
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and P = 0.034, respectively, using the Mann-Whitney
test; fig 4-(d)). Otherwise, no significant differences were
observed, except for the effect on RGM249 mRNA.
Similar to transfectants that received RGM249 siRNA,
telomerase activity in transfectants with shRNA was
suppressed in the same manner as mRNA expression,
compared with that in transfectants with LacZ shRNA
(fig 4-(e)). Telomere length was not measured due to the
s m a l ln u m b e ro fc e l l sa v a i l a b l ea n dt h er e l a t i v e l ys h o r t
observation period. No immunoreactive effects on
tumor cell proliferation resulting from cytokine storm
were recognized in the GE profile by microarray analysis,
which resulted in IFN-b being downregulated twofold.
The effects of overexpressing RGM249 mRNA
In the transfection of HLF or A172 cells showing
RGM249 overexpression, as distinct from the transfec-
tion of other cell lines such as senescing or well-
differentiated cells, hTERT mRNA was significantly
downregulated. In particular, the growth of A172
transfectants was strongly suppressed and they were
induced to undergo senescence. On the other hand,
hTERT mRNA was upregulated in KMST cells, which was
established by exposure to chemical oncogens (Addi-
tional file 1). However, the expression of hTR, b-actin,
and RPL22 mRNA showed no significant differences
between mock transfectants and RGM249 transfectants
in KMST cells, similar to the transcriptional level of
c-Myc, undifferentiated markers (Rex-1 and GATA4), and
an initiation factor (eIF6). Additionally, the longevity
and proliferation rate of transfectants were almost the
same as those of the parental cells or mock transfectants.
Interestingly, we examined the effect of RGM249 shRNA
wrapped by cationized carriers on tumorigenesis in nude
mice using local or venous injection, which resulted in
more than 60% of the suppressive effect in vivo (manu-
script in preparation). FACS analysis showed that
RGM249 mRNA expression introduced more than half
of RGM249 pRNAT/U6.1/neo/GFP-transfected popula-
tions into the preG1 phase (fig 5-(a)), senescence, and
apoptosis (fig 5-(b)), compared with pRNAT/U6.1/neo/
GFP-transfectants. These phenotypic changes were simi-
lar to the effects of RGM249 shRNA, compared with
those of LacZ shRNA
LOH in human hepatocellular carcinoma (HCC) is rare,
except at 10q26.11-qter, which is observed in 25% of
HCC cases (32). However, relatively frequent alterations
and deletions of chromosome 10p have been identified
in human tumors, including glioblastoma multiforme
(GBM) and malignant melanoma [33, 34]. In GBM, 3
common distinct regions of chromosome 10 deletion
have been frequently identified; one of them is the distal
half of the short arm [15, 35], indicating that several
distinct tumor suppressor genes may be present on
chromosome 10 and may contribute to the progression
of malignant tumors. Structural alterations have only
been observed in malignant melanoma (10p13-pter),
gastric cancer (10p15), and GBM (10p14-pter). Unex-
pectedly, RGM249 with low GC ratio on 10p15.3 is
potently miRNAs-generating gene, as well as cancer-
related gene.
It is well known that a miRNA, generated from a miRNA
precursor gene, can act as a new regulator which induces
cancer cell lines to adopt a suppressive phenotype,
except for the tumor suppressor gene. Because the
phenotype we observed in a series of transfections with
a chromosome (fragment) or BAC was suppressed, this
miRNA might be a Suppressor-miR or it might have
demonstrated a miRNA-directed inhibition. Actually,
RGM249 repressed hTERT mRNA in A172 cells derived
from GBM, moderately differentiated HCC (HMc-Li7),
and poorly differentiated HLF. Beyond 60S RPL22,
which we referred to in this study, several ribosomal
protein mRNAs changed their expression level after the
introduction of siRNA or shRNA into cell lines or tumors
inoculated in nude mice (data not shown). In a miRNA-
mediated mRNA repression study, RPL22, of which
Greider et al. previously referred to as one of the binding
protein to hTR that is essentially required for telomere
maintenance and telomerase activity in normal tissues
a n dd i s e a s e ,s h o w e dn os i g n i f i c a n ta l t e r a t i o ni ne x p r e s -
sion level, whereas it showed an obvious change in
siRNA-directed RNAi with reproducibility (2.08-fold
downregulation in microarray analysis)[31]. We do not
have any definite evidence that RPL22 functions in
association with hTERT expression during carcinogenesis
or in hypoxic tissues. However, while endogenous hTR
expression is regulated at the transcriptional level, hTERT
is regulated by alternative splicing under hypoxic
conditions [36]. It may be that RPL22 influences
hTERT expression through hTR expression. RGM249
dsRNA repressed RPL22. However, RGM249 siRNA and
shRNA did not significantly repress RPL22 because of the
high homology shared by 2 parts of the RGM249
sequence which are different from the functional
sequence, which was used in siRNA or shRNA and
corresponds to one part of the RPL22 sequence.
Eukaryotic initiation factor 6 (eIF6) has long been
knowntobindtofree60Sribosomalsubunits,preventing
the assembly of translationally competent 80S ribosome
particles [37]. Similar to eIF4E bound to Argonaute2
(Ago2), which regulates mRNA expression by cleaving its
mRNA targets and competing with eIF6 for the mRNAcap
[38], eIF6 may mediate siRNA-directed RNA interference
rather than miRNA-directed translational repression. This
study indicates that the sequence focused for siRNA or
BMC Molecular Biology 2009, 10:5 http://www.biomedcentral.com/1471-2199/10/5
Page 7 of 16
(page number not for citation purposes)shRNA has a key function in this gene, and that RGM249
may functionally have a close link to gene-mediated
processes at the transcriptional level, such as RNA
biogenesis or gene regulation, and a link to ribonucleo-
proteins such as telomerase or RPL22. As a result, RNA
molecules may induce suppressive or apoptotic events in
cancer cells through an RGM249-related signaling path-
way involved in a DNA-, RNA-, or protein-binding
function (some of the significantly changed genes are
shown in fig 6; there were 306 upregulated genes and 144
downregulated genes in the in vitro trial)
miRNA is physiologically generated by both Drosha and
Dicer. We can not digest RGM249 mRNA by Drosha
because Drosha protein is now unavailable commer-
cially. RGM249 RNA processed by DICER, results in at
least 3 small fragments of a product (17–23 bp) related
to RNA species (fig 3-(c)). The sequencing of diced
RGM249 mRNA proved that the sequence we used for
siRNA or shRNA was included in fig 3-(b). Because the
silencing of RGM249 induced the downregulation of
hTERT expression, this gene may be involved in the
oncogenic mechanism. In humans, ~800 miRNAs are
Figure 5
FACS analysis and phenotypes in transfectants by RNAi methods. (a) FACS analysis showing induction of more than
half of the transfected populations into the preG1 phase of the cell cycle. As shown in the upper two parts, the increase in
apoptotic cells in transfectants by RGM249 is shown as red circled areas. DNA content analysis revealed in the lower parts, that
earlycellsshowedtypicalcellproliferation profile,cellslaterinproductionshowedreducedcellproliferation,and latercellsalso
showed early signs of cell death (sub-G1), in both transfectants. In the bottom parts, the histogram with gating and the threshold
were set properly for correctly stained cells in a clean machine. The large pink peak represents the green light signal from cells.
The line segment flanking the peak is the gating band for cells. (b) Changes in phenotypes of HLF cells receiving LacZ shRNA or
RGM249 shRNA are shown. The upper, middle, and bottom part shows the phenotype of transfectants, the result of b-Gal
staining as an indicator of senescence, and EGFP expression as evidence of successful transfection, respectively. At 2–3 weeks
after transfection, the transfectants were induced to undergo apoptosis (upper and bottom parts) through senescence (middle
part) in the presence of both a selectable marker (neo) and RGM249 (data not shown).
BMC Molecular Biology 2009, 10:5 http://www.biomedcentral.com/1471-2199/10/5
Page 8 of 16
(page number not for citation purposes)predicted to exist [39]; each of these is thought to have
hundreds of targets, suggesting that miRNAs play a
critical regulatory role in cellular protein expression [40].
In various human cancers as well as in developmental
timing and patterning, differentiation, organogenesis,
and stress response, alterations of miRNA profiles have
been observed; these miRNAs may act as oncogenes,
leading to the specific dysregulation of their target gene
transcripts [41, 42]. Although alterations in miRNA
expression have been described in cancer and may
contribute to other disease states, it remains unclear
what drives these alterations. Our findings might pave
the way for defining unknown crucial roles that miRNAs
located around this locus play in oncogenic regulation
through hTERT regulation and, in particular, the role
R G M 2 4 9m a yp l a yd u r i n gt h i sp r o c e s s .
Although the way in which RGM249 regulates hTERT
remains unidentified, the physiological expression of
RGM249 synchronizes the upregulation of hTERT
mRNA, and its excess expression using the RNA-expres-
sion vector downregulated hTERT in specific cancer cells.
Moreover, its siRNA or shRNA suppressed hTERT. Taken
together, RGM249 may function negatively or positively,
reversibly or indirectly on unknown mediators upstream
of hTERT. Using microarray analysis between transfec-
tants with RGM249 siRNA and those with LacZ siRNA
(fig 6), the comparative expression analysis demon-
s t r a t e dt h a tA T Ma n dT P 5 3 L Pw e r eu p r e g u l a t e d ,
although p53 status (the presence of mutation) in each
cell line did not correlate with hTERT mRNA expression,
and Ras and several transcriptional factors were down-
regulated. As described in fig 6, RGM249 may have direct
Figure 6
A representative gene expression in microarray analysis. Representatives of regulated genes using microarray analysis
performed between transfectants with LacZ shRNA and RGM249 shRNA are shown as a gene symbol (description) and ×fold.
Following transfection of the RNA generating-vector and presumably the generation of RNA molecules, many transcriptional
factors, the molecules involved in RNA biogenesis, and tumor-related genes altered the expression level.
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induced by siRNAs may induce upregulation of genes
participating in both repairing action and apoptotic or
growth inhibition induction. Comparative proteome
analysis would be useful to explain the detailed
mechanisms underlying these processes. The overexpres-
sion of RGM249 in normal cells did not alter hTERT
expression level, suggesting that RNA-related molecules
may be functionally different in normal cells and de-
differentiated cells, and that a key molecule for
uncovering the oncogenesis mechanism or a potential
factor which could be applied as a therapeutic target may
exist in the genome. The findings that both the
overexpression and dsRNA knockdown of RGM249
suppressed the expression of hTERT are problematic. In
addition, this gene may be indirectly associated with
hTERT because its overexpression may not always reveal
a normal function and RGM249 microRNAs are not
predicted to bind to hTERT even with the use of available
bioinformatics. Moreover, this gene is not mutated or
homozygously deleted even in HCC cells and tissues.
B a s e do nt h eC e l e r aa s s e m b l y ,i ts e e m st oh a v eo n eb a s e
(T) addition at position 188 of the first exon, however,
single nucleotide polymorphisms are not specific to
cancer. Additional experiments such as promoter analy-
sis are needed to elucidate the epigenetic network in
which this gene works.
This novel noncoding gene is strongly expressed in poorly
differentiated tumor cells. The genes (mRNAs) targeted
commonly by both miRNAs and siRNAs in our study were
MAPK6 and PRKCA, which can induce hTERT upregulation
(fig 7-(a)). Representative genes (mRNAs) targeted by
miRNAs with expression upregulated more than twofold
by shRGM249RNA included DICER1, high mobility group
A2 (HMGA2) and GAS7, as well as hsa-miR-let 7b, 7d, 7e,
7f, and 7g targets. In particular, RGM249 might be
implicated inoncogenic transformation through the inhibi-
tionof HMGA2interactingwithlet-7miRNA(fig7-(b),(c))
[43]. RGM249 was not detected in any 'mirtrons or
polycistron' detection program, genome, or miRNA data-
base (MiRscan, PicTar, miRanda, etc.)[44]. We are now
considering MED18 as a key molecule obtained from
microarray analysis (fig 6 and 7) [45]. The mediator head
module stimulates basal RNA pol II transcription and
enables transcriptional regulation. The head subunits
MED8, MED18, and MED20 form a subcomplex (MED8/
18/20) with 2 submodules. The highly conserved N-
terminal domain of Med8 forms one submodule that
binds the TATA box-binding protein (TBP) in vitro and is
essential in vivo. Beyer et al. reported that the down-
regulation of another mediator complex (MED28) expres-
sion in NIH3T3 cells results in a significant induction of
several genes associated with smooth muscle cell (SMC)
differentiation and functions as a repressor of SMC
differentiation [46]. A mediator complex is essential for
transcriptioninducedbypolIIineukaryotesandisrequired
for the recruitment of the transcription machinery after
chromatin remodeling [47]. MED18 may also be involved
in the repression of differentiation, transcription, and
telomere elongation. Microarray analysis revealed a strong
upregulation of MED18 (×24.8), the RNA polymerase II
mediator which functions as a coactivator involved in
transcription regulation in nearly all RNA polymerase II-
dependent genes, and other RNA-related or DNA-binding
geneswereupregulated(fig6).IntransfectantswithMED18
siRNA, both RGM249 and hTERT mRNA were significantly
upregulated (Supplement fig 2-(d)). MED18 siRNA trans-
fected into A172 cells significantly upregulated hTERT
mRNA and RGM249 expression (Additional file 1-(d)).
Co-transfection by both MED18 siRNA and hTERT siRNA
upregulatedonlyRGM249mRNA,suggestingthatRGM249
may functionally locate upstream hTERT mRNA, and
MED18 may closely interact with RGM249. Overexpressing
RGM249 is carried out for the purpose of comprehending
the possible suppressive effects of miRNAs and depleting
RGM249isperformedforthe purpose of understanding the
physiological function of this gene. Our results suggest that
RGM249maynotbeaprecursorgenesuchasOnco-miRbut
is a Suppressor-miR and might function to lower differ-
entiationinitsexpressingcellsby suppressing cell growth as
an independent response to hTERT expression.
Conclusion
Taken together, the enhanced cell death in RGM249
transfectants likely resulted from an hTERT-independent
mechanism or the presence of a mediator with crucial
responsibility for oncogenesis, arguing that some other
targets instead of hTERT might be the real players
mediating these contradictory oncogenic and growth
suppressive functions. It should be noted that mRNA
studies do not always reflectp r o c e s s e sa tt h ep r o t e i n
level of gene regulation.
Further studies will be required to investigate these
expression levels. Several ncRNAs in the exons we
trapped might provide new insights into the coordinated
and dynamic mechanisms of development, stress,
transformation, and (de)differentiation, resulting in the
possible prevention of oncogenesis and suppression of
tumor progression.
Methods
DNA preparation and analysis
BACclones(H-11,M-6,andJ-21) wereselectedonthe basis
of results from a previous experiment (Research Genetics,
Toronto, Canada) [18]. BAC DNA was isolated using a
modified alkaline lysis protocol [18]. Pulsed-field
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(page number not for citation purposes)electrophoresis analysis of the isolated BAC DNA was
performedusingtheCHEFDRIIsystem(Bio-Rad,CA,USA).
Sequence determination and analysis, and construction of
a contig of BAC clones (M-6, H-11, and J-21)
Purified BAC DNAs were shared using the AERO-MIST
nebulizer (CIS-US, Bedford, MA, USA) and after ligation of
adapters, these DNAs were subcloned into the BstXI sites of
pSHOT II, which was constructed by subcloning the BstXI
sites from pcDNA II, prior to the disclosure of the
endosequences of the 3 BAC clones (M-6, H-11, and J-21)
(fig1-(b)).Asequencinglibrarywasgeneratedbysonicating
BAC and cloning it into a phosphatased EcoRV site in
Bluescript; initially, each clone was sequenced using Phil
Greene's Phred and Phrap programs.
Exon trapping
For all exon trapping experiments, we used the exon-
trapping system kit (Gibco-BRL, Gaithersburg MD, USA)
and the supplements recommended therein. We
(a) Representative genes predicted to be commonly 
Targeted by RGM249 miRNAs or siRNAs
Genes targeted by miRNAs changed more than
twofold by shRGM249RNA 
(c)
hsa_miR_192
GAS7
RAD51 like 3
MAPK2K4
H3 histone 3B
DYRK1A
DYRK3
RB1
RAB2A
GPR22
GPR23
ZEB2
LARP4
CTNNBIP1
BLCAP
hsa_miR_196a
GAS7
HOXA5, A7, A9 
HOXB7, C8
GATA6
LARP4 
NRAS
HMGA2
DICER1
MAPK4K3
P27/kip1
CYCLINT
RhoGTPase
PDGFRA
CCND2
hsa_miR_222
DYRK1A
miRNAs upregulated by shRGM249 transfection (b)
CUGACCUAUGAAUUGACAGCC
UCACCCUUCCAUAUCUAGUCU
AAGUGCUGUCAUAGCUGAGGUC
UAGGUAGUUUCAUGUUGUUGG
AGCUCGGUCUGAGGCCCCUCAG
UCUACAAAGGGAAGCCCUUUCUG
AGCUACAUCUGGCUACUGGGUCUC
Mature sequence
hsa_miR_192
rno_miR_336
hsa_miR_512_3p
hsa_miR_196a
hsa_miR_423
hsa_miR_520d_AS
hsa_miR_222
miRNA description name
miRNAs
miR 26a
miR-147
miR-195
miR-368
Oxidation associated genes
GPX1, 2, & 4
COX5b, 6, & 7b
MTCO1
NOX3 & 5
DUOX2
RAS-associated genes
MAPK1, 4, & 6
AKT1
PRKCA
Figure 7
A representative miRNA expression in microRNAarray analysis and predictive target genes. (a) Representative
genes predicted to be commonly targeted by RGM249 miRNAs or siRNAs are shown. 4 miRNAs were predicted from the
RGM249 sequence by miRBase http://microrna.sanger.ac.uk/sequences/index.shtml or miRNAMAP http://mirnamap.mbc.nctu.
edu.tw/html/search.html and it was predicted that the miRNAs might inhibit the translation of genes involved in oxidation and
RAS activation. As reported previously in association withh T E R Te x p r e s s i o n ,P R K C A ,M A P K 1 ,a n dA K T 1w e r ei n c l u d e di n
the targeted genes. (b) Seven miRNAs upregulated more than twofold in RGM249 shRNA-transfectants by microRNAarray
analysis performed between transfectants with LacZ shRNA and RGM249 shRNA are shown. Some of these 7 miRNAs have
been indicated in the oncogenesis of oral squamous cell carcinoma (unpublished data). (c) Representative genes targeted by
miRNAs which changed more than twofold when induced by shRGM249RNA are shown. The genes were predicted mainly
using miRNAMAP. Three miRNAs were presumably targeted towards miRNA processing proteins, transcriptional factors,
telomere-related genes, TERT-related genes, tumor suppressor-related genes, and cell cycle-related genes.
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(page number not for citation purposes)shotgunned M-6, H-11, and J-21 into pSPL3, employing
B a m H Ia n dB g l I Io rB a m H I ,B g l I I ,a n dP s t If o r2w a y so f
cutting BAC DNA using restriction enzymes. This
method was performed as described previously [21].
Thereafter, the BAC whole sequence or cDNA sequence
was identified using a database http://www.ncbi.nlm.
nih.gov/. In 1999 to 2005, the sequenced reference
human genome draft was not definitely determined on
10p14–15 and altered several times during this interval.
Northern blotting, reverse-transcriptase polymerase chain
reaction (RT-PCR), and onestep real-time RT-PCR for
confirming the expression of exons in human organs
The probe, consisting of the respective exons, including two
exons forming RGM249, radiolabeled by random priming
using the Radprime kit (Gibco-BRL), was incubated with
human multiple tissue northern blot (Human 12-Lane
MTN Blot) (Clontech, Mountain View, CA, USA). One-step
real-time RT-PCR experiments were performed using
Human Total RNA Master Panels (Clontech) according to
methods we previously reported using LightCycler (Roche,
Basel, Switzerland) [48]. The primer sequences used are
shown in Table 1. Each quantification was confirmed
by sequencing with high reproducibility (for RGM249;
fig 2-(a), r = 0.998, for hTERT) [48].
cDNA cloning and exon/intron organization
Using the exons identified by Northern blotting or RT-
PCR, we amplified cDNA fragments from human skeletal
muscle and liver "Marathon-ready" cDNA, according to
the manufacturer's protocol (Clontech). Amplicons were
subcloned into the pcDNA3 vector (Invitrogen, Leek, The
Netherlands). A comparison of cDNA and genomic
sequences revealed a total of 20 exons and detected 3
alternative splice donor sites for 6 exons.
PCR-single-strand conformation polymorphism (SSCP)
analysis for the detection of mutations in exons
To screen for point mutations in trapped exons, we
performed PCR-SSCP assays using flanking intron
primers, as previously described [49].
Measurement of telomerase activity
To confirm telomerase activity in transfectants after
siRNA transfection, a telomerase detection kit, TRAP-eze,
(Oncor Inc., Gaithersburg, MD, USA) used for RGM249
cloning and the TeloChaser kit (TOYOBO, Osaka, Japan)
used for the expression analysis of shRNA transfectants,
were employed for the telomeric repeat amplification
protocol assay according to the manufacturer's protocol.
Quantification of TRAP was estimated using an image
analyzer (CS Analyzer 3) provided by ATTO Corp.
(Tokyo, Japan).
Structural prediction of RGM249
To examine whether RGM249 can generate a protein, we
performed an in vitro translation assay according to the
manufacturer's instructions (Clontech). After examining
the motif and homology http://www.ncbi.nlm.nih.gov/
genome/seq/BlastGen/BlastGen.cgi?taxid=9606; http://
hmmpfam.ddbj.nig.ac.jp/; http://blast.ncbi.nlm.nih.
gov/Blast.cgi), we predicted the secondary structure of
RGM249 using the Vienna RNA Secondary prediction
and comparison program http://www.tbi.univie.ac.at/
~ivo/RNA/; http://www.genebee.msu.su/services/rna2_r-
educed.html). Subsequently, we screened the micro
RNA) (miRNA) database among species. To confirm
whether the RGM249 gene functions as a miRNA
precursor gene, we digested the full-length RNA with a
Dicer enzyme using a Dicer siRNA generation kit
according to the manufacturer's protocol (Gene Therapy
Systems, Inc., CA, USA).
RGM249 mRNA expression in human organs,
hepatocytes, hepatoma cell lines, and liver tissues
To confirm the transcriptional level (copy number) in
human organs, liver-related normal cells, and immorta-
lized cells, we performed one-step real-time RT-PCR
using human hepatocytes (KAC, Kyoto, Japan), hepa-
toma cell lines (Tohoku University, Sendai, Japan), and
74 surgically resected liver tissue samples, including 33
pairs of hepatomas and corresponding adjacent tissues.
Table 1: Representative primer sequences used in this study
Gene Oligonucleotide Sequence (5'-3')
RGM249 (for RT-PCR) sense primer TGAGAGAATGGGTGTCCAAG
antisense primer CCTGGAAAGTCTAGGGATGT
RGM249 (for real-time RT-PCR) sense primer AGAGAATGGGTGTCCAAGAGG
antisense primer GGACATGTTCAGCTTCCCCTTT
hTERT sense primer CGGAAGAGTGTCTGGAGCAA
antisense primer GGATGAAGCGGAGTCTGGA
RPL22 (for RT-PCR) sense primer ATTGCACCCACCCTGTAGAA
antisense primer TGTTAGCAACTACGCGCAA
RPL22 (for real-time RT-PCR) sense primer GACCATCGAAAGGAGCAAGA
antisense primer TGTTAGCAACTACGCGCAAC
b-actin sense primer TCACCCACACTGTGCCCATCTACGA
antisense primer CAGCGGAACCGCTCATTGCCAATGG
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the average.
Effect of RGM249 overexpression on expression of
other genes in RGM249 transfectants
After ligasing a synthesized RGM249 (Operon Bio-
technologies, Tokyo, Japan) into the pRNAT/U6.1/Neo/
GFP vector (GeneScript Corp., Piscataway, NJ, USA)
digested at the KpnI/SacI site, it was transfected into
several cell lines (A172, T98G, HLF, HT1080, HeLa,
SW480, Huh7, HepG2, HMc-Li7, KMST-6, SUSM-1, and
NIH3T3), with NH-12 as senescence-programmed cell
lines, and keratinocytes and TIG 1–20 as primary cells.
Immortalized cells were transfected with FuGene (Roche,
Basel, Switzerland) to obtain stable cells overexpressing
RGM249. After enhanced green fluorescent protein
expression in the presence of a neomycin-resistant gene
in all cell types was confirmed, b-gal staining (Senes-
cence Detection kit; BioVision, CA, USA) and RT-PCR
were performed. Primary cultured cells were electropo-
rated using Nucleofector technology (Amaxa AG,
Cologne, Germany) under optimal conditions. At least
5 transfectants were examined in mock or RGM249
transfectants. The respective gene expression (GE) ratio
to b-actin mRNA in mocks or RGM249 tranfectants was
analyzed using the Mann-Whitney test. Between both
transfectants, FACS analysis of HLF cells was performed
using Guava EasyCyte Mini according to the manufac-
turer's instructions (GE Healthcare UK Ltd., Buckin-
ghamshire, England).
Transfection of total dsRNA and gene-specific siRNA
derived from the RGM249 gene
dsRNA derived from the RGM249 sequence was gener-
ated from the expression vector with RGM249 in the
MCS of Litmas28i (NEB, MA, USA) using an in vitro
transcription method (T7 RiboMAX Express Large Scale
RNA Production System, Promega, Madison, WI, USA)
and was transfected into 4 hepatoma cell lines (HLF,
Alexander, HepG2, and HMc-Li7) at a concentration
range of 10–40 μg/ml medium. Subsequently, to avoid
unspecific inhibition of dsRNA through interferon (INF)
activation [50, 24], stealth siRNAs were designed on-line
using RNAi designer provided by Invitrogen (Tokyo,
Japan). At the optimal concentration (25 nM) of siRNA
to the recipient (HLF), which expresses it strongly, we
repeatedly performed transfections to examine the
correlation of telomerase-related factors (hTR, TEP1,
dyskerin, RPL22, etc.) with RGM249 expression [31]. The
expression of telomerase-related genes was estimated by
RT-PCR after transfection of dsRNA (fig 4-(a)).
siRNA method
Two kinds of siRNAs (siRNA ① and siRNA ②)w e r e
designed using the Stealth RNAi designer and synthe-
sized by Invitrogen (Invitrogen Corp, Carlsbad, CA,
USA). The sequences are shown in Table 2. To suppress
RGM249 expression with siRNA, we performed the
following transfection procedures in HLF cells: transfec-
tion using Stealth siRNA ①, transfection employing
Stealth siRNA ②, and transfection with both Stealth
siRNA ① and Stealth siRNA ② at a final concentration of
25 nM as an optimal condition. We collected transfec-
tants 24 hours after transfection for RNA extraction and
confirmed the inhibitory effect on RGM249 expression
by one-step RT-PCR. HLF cells treated with FuGene
Reagent without siRNAs and with Stealth LacZ siRNA
were used as controls. Transfectants were collected 48
hours, 1 week, and 2 weeks after transfection. Subse-
quently, we confirmed the suppressive effect of shRNA
w i t ht h es a m ef u n c t i o n a ls e q u e n c ea st h a to fs i R N Ao n
RGM249 expression, using the BLOCK-iT RNAi
Expressing vector (Invitrogen) which was designed to
generate shRNA in transfectants. To examine the effect
Table 2: siRNA and shRNA sequence used in this study
Stealth siRNA ① Sequence (5'-3')
top strand UUCCCUUUGUCUAGCCUUAUUCUGC
bottom strand GCAGAAUAAGGCUAGACAAAGGGAA
Stealth siRNA ②
top strand AUACUGUGAGAUUCGAGGAUCAUAC
bottom strand GUAUGAUCCUCGAAUCUCACAGUAU
RGM249 shRNA Sequence (5'-3')
top strand CACCGCAGAATAAGGCTAGACAAAGCGAACTTTGTCTAGCCTTATTCTGC
bottom strand AAAAGCAGAATAAGGCTAGACAAAGTTCGCTTTGTCTAGCCTTATTCTGC
RGM249 mt-1
shRNA
top strand CACCGCAGAATAAGGCTAGACAAAGCGAACTTTGTCAGCCTTATTCTGC
bottom strand AAAAGCAGAATAAGGCTGACAAAGTTCGCTTTGTCTAGCCTTATTCTGC
RGM249 mt-2
shRNA
top strand CACCGCAGAATAAGGCTAGACAAAGCGAACTTTGTCTAGCCTTATTTGC
bottom strand AAAAGCAAATAAGGCTAGACAAAGTTCGCTTTGTCTAGCCTTATTCTGC
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(page number not for citation purposes)on hTERT expression 7 to 10 days later after selection
with 200 μg/ml Zeocin, an shRNA-generating lentiviral
vector with the functional sequence of RGM249
(fig 3-(b)) was transfected. Since the mock of the
lentiviral vector was linearized according to the manu-
facturer's instructions, we used transfection reagents
without RNA and the vector, LacZ shRNA as the controls,
and wtRGM249 or mtRGM249 (mt-1 or mt-2) with one
base (T or C) deletion in the wtRGM249 sequence. We
evaluated GE in the transfectants semiquantitatively.
Stealth siRNA and shRNA sequences for RGM249 are
shown in Table 2.
Gene expression profile by microarray analysis
Microarray analysis was performed for total RNA purified
from transfectants with LacZ shRNA and from those with
RGM249 shRNA following confirmation of the down-
regulation of both RGM249 and hTERT mRNA expression
by RT-PCR after strict quality control in accordance with
the guidelines of the Hokkaido System Science (Sapporo,
Japan). Data for genes that had changed more than
twofold were additionally analyzed using Gene Ontology
Tree Machine http://bioinfo.vanderbilt.edu/gotm/ and
typical GE changes are shown in fig 6 and the left fig in
Additional file 2. miRNA array analysis was performed
using the same samples as the microarray analysis
samples (Filgen, Inc., Nagoya, Japan). The results are
shown in fig 7(b) and the right fig in Additional file 2.
Genes targeted by miRNAs were investigated using
DIANA-microT, Pictar, TargetScan, and miRanda
http://diana.pcbi.upenn.edu/cgi-bin/TargetCombo.cgi.
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Additional file 1
A comparison of hTERT mRNA expression between mock and
RGM249 transfectants. In response to upregulated RGM249 mRNA,
hTERT mRNA did not induce any significant change in senescence-
programmed cells (keratinocytes, TIG1-20, and NH-12) except for
KMST-6 cells. The dotted line indicates hTERT mRNA expression in
parental cells. Six transfectants were examined in both mock and
RGM249 transfectants. (b) Actin mRNA and RPL22 mRNA showed no
significant difference among untransfected cells and mock or RGM249
transfectants in the 4 cell lines described in (a). (c) Comparison of
hTERT mRNA expression between mock and RGM249 transfectants. In
response to upregulated RGM249, hTERT mRNA induced a significant
change in suppression in (left) HLF cells (poorly differentiated
hepatoma) and (right) A172 cells (glioblastoma). The dotted line
indicates mean mRNA expression in untransfected parental cells. hTR
mRNA and b-actin mRNA showed no significant differences in b-actin,
hTERT, RGM249, and hTR among untransfected cells and mock or
RGM249 transfectants. (d) By transfection of MED18 siRNA or
MED18/hTERT siRNA into A172 cells, an insight into the regulative
network among 3 genes (RGM249, MED18, and hTERTmRNA) could
be obtained. The number of respective inductions was more than 5.
Following transfection of MED18 siRNA, both TERT mRNA and
RGM249 mRNA were significantly upregulated (P < 0.01). Following
co-transfection of MED18 siRNA and TERT siRNA, RGM249 mRNA
was significantly upregulated (P < 0.05).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2199-10-5-S1.pdf]
Additional file 2
A representative case of microarray analysis and microRNAarray
analysis. Microarray analysis (a) and miRNA array analysis (b) were
performed for total RNA purified from transfectants with LacZ shRNA
and from those with RGM249 shRNA. The representative analyses are
demonstrated, respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2199-10-5-S2.pdf]
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